Clinical Trial Update: SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating standard-of-care chemotherapy with or without tocilizumab for metastatic breast cancer, including triple-negative and estrogen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Kathy Miller | Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING